Literature DB >> 18460720

Limitation of fractional flow reserve in evaluating coronary artery myocardial bridge.

Inder M Singh1, Roopa A Subbarao, Saihari Sadanandan.   

Abstract

Symptomatic myocardial bridge is treated with medical therapy, but in refractory cases, percutaneous revascularization has been used. We describe two cases to highlight differences in coronary compression and flow pattern, which make the luminal narrowing associated with a myocardial bridge anatomically and physiologically different from the fixed stenosis of atherosclerotic epicardial disease. Due to these characteristics, evaluating the functional severity of a myocardial bridge using fractional flow reserve as a guide to revascularization may be of limited value. Furthermore, stenting, including drug-eluting stents, may not be the ideal revascularization strategy secondary to a higher risk of in-stent restenosis.

Entities:  

Mesh:

Year:  2008        PMID: 18460720

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  4 in total

1.  Angina Relief by Ranolazine Identifies False-Negative SPECT Myocardial Perfusion Scans in Patients with Coronary Disease Demonstrated by Coronary Angiography.

Authors:  Gary L Murray
Journal:  Int J Angiol       Date:  2014-09

2.  Performing and Interpreting Fractional Flow Reserve Measurements in Clinical Practice: An Expert Consensus Document.

Authors:  Stephan Achenbach; Tanja Rudolph; Johannes Rieber; Holger Eggebrecht; Gert Richardt; Thomas Schmitz; Nikos Werner; Florian Boenner; Helge Möllmann
Journal:  Interv Cardiol       Date:  2017-09

3.  Case of angina pectoris at rest and during effort due to coronary spasm and myocardial bridging.

Authors:  Hiroki Teragawa; Yuichi Fujii; Tomohiro Ueda; Daiki Murata; Shuichi Nomura
Journal:  World J Cardiol       Date:  2015-06-26

Review 4.  Clinical Relevance of Coronary Fractional Flow Reserve: Art-of-state.

Authors:  Yohanes Adiputra; Shao-Liang Chen
Journal:  Chin Med J (Engl)       Date:  2015-05-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.